New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:17 EDTCERUCerulean reports Q2 EPS (44c), consensus (36c)
Reports Q2 revenue $33K. As of June 30, Cerulean had cash and cash equivalents of $64.3M. Cerulean estimates that its current cash and cash equivalents will allow it to fund several ongoing single-arm clinical trials of CRLX101, an ongoing randomized Phase 2 clinical trial of CRLX101, and a planned Phase 1 trial of CRLX301. CEO Oliver Fetzer said, "We anticipate announcing data from two ongoing single-arm CRLX101 trials in the first quarter of 2015, data from an ongoing randomized CRLX101 trial by the end of 2015, and data from a planned Phase 1 CRLX301 trial by the end of 2015."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
13:53 EDTCERUCerulean management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use